IAP gene deletion and conditional knockout models

Seminars in Cell and Developmental Biology

Volumn 39, Issue , 2015, Pages 97-105

  Silke, John ^a,b   Vaux, David L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BIR; Birc; Gene deletion; IAP; NAIP; Survivin

Indexed keywords

AURORA B KINASE; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN;

APOPTOSIS; CHROMOSOME SEGREGATION; DROSOPHILA; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HUMAN; INNATE IMMUNITY; MITOSIS; MULTIGENE FAMILY; NONHUMAN; REVIEW; WORM; YEAST; ANIMAL; CHEMISTRY; FEEDBACK SYSTEM; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE;

INVERTEBRATA; MAMMALIA; MUS;

ANIMALS; CHROMOSOME SEGREGATION; FEEDBACK; GENE DELETION; GENE KNOCKOUT TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE;

EID: 84928204838     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.12.004     Document Type: Review

References (117)

1. Hay B.A., Wassarman D.A., Rubin G.M. Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. Cell 1995, 83:1253-1262.
2. Cullen K., McCall K. Role of programmed cell death in patterning the Drosophila antennal arista. Dev Biol 2004, 275:82-92.
3. Harlin H., Reffey S.B., Duckett C.S., Lindsten T., Thompson C.B. Characterization of XIAP-deficient mice. Mol Cell Biol 2001, 21:3604-3608.
4. Silke J., Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol 2013, 5.
5. Burstein E., Ganesh L., Dick R.D., Van De Sluis B., Wilkinson J.C., Klomp L.W., et al. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J 2004, 23:244-254.
6. Olayioye M.A., Kaufmann H., Pakusch M., Vaux D.L., Lindeman G.J., Visvader J.E. XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. Cell Death Differ 2005, 12:87-90.
7. Mufti A.R., Burstein E., Csomos R.A., Graf P.C., Wilkinson J.C., Dick R.D., et al. XIAP is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell 2006, 21:775-785.
8. Schile A.J., García-Fernández M., Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev 2008, 22:2256-2266.
9. Jost P.J., Grabow S., Gray D., McKenzie M.D., Nachbur U., Huang D.C., et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009, 460:1035-1039.
10. Rigaud S., Fondanèche M.C., Lambert N., Pasquier B., Mateo V., Soulas P., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444:110-114.
11. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B., et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010, 116:1079-1082.
12. Marsh R.A., Villanueva J., Kim M.O., Zhang K., Marmer D., Risma K.A., et al. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol 2009, 132:116-123.
13. Rumble J.M., Oetjen K.A., Stein P.L., Schwartzberg P.L., Moore B.B., Duckett C.S. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell Immunol 2009, 259:82-89.
14. Krieg A., Correa R.G., Garrison J.B., Le Negrate G., Welsh K., Huang Z., et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci U S A 2009, 106:14524-14529.
15. Damgaard R.B., Nachbur U., Yabal M., Wong W.W., Fiil B.K., Kastirr M., et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 2012, 46:746-758.
16. Speckmann C., Lehmberg K., Albert M.H., Damgaard R.B., Fritsch M., Gyrd-Hansen M., et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013, 149:133-141.
17. Damgaard R.B., Fiil B.K., Speckmann C., Yabal M., zur Stadt U., Bekker-Jensen S., et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med 2013, 5:1278-1295.
18. Zeissig Y., Petersen B.S., Milutinovic S., Bosse E., Mayr G., Peuker K., et al. XIAP variants in male Crohn's disease. Gut 2014, 64:66-76.
19. Kobayashi K., Inohara N., Hernandez L.D., Galán J.E., Núñez G., Janeway C.A., et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194-199.
20. Bertrand M.J., Doiron K., Labbé K., Korneluk R.G., Barker P.A., Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009, 30(6):789-801.
21. Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J., et al. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS ONE 2011, 6:e22356.
22. Conze D.B., Albert L., Ferrick D.A., Goeddel D.V., Yeh W.C., Mak T., et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol 2005, 25:3348-3356.
23. Silke J., Kratina T., Chu D., Ekert P.G., Day C.L., Pakusch M., et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci U S A 2005, 102:16182-16187.
24. Rajalingam K., Sharma M., Paland N., Hurwitz R., Thieck O., Oswald M., et al. IAP-IAP complexes required for apoptosis resistance of C. trachomatis-infected cells. PLoS Pathog 2006, 2:e114.
25. Feltham R., Bettjeman B., Budhidarmo R., Mace P.D., Shirley S., Condon S.M., et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem 2011, 286:17015-17028.
26. Conze D.B., Zhao Y., Ashwell J.D. Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 2010, 8:e1000518.
27. Giardino Torchia M.L., Conze D.B., Ashwell J.D. c-IAP1 and c-IAP2 redundancy differs between T and B cells. PLoS ONE 2013, 8:e66161.
28. Enwere E.K., Holbrook J., Lejmi-Mrad R., Vineham J., Timusk K., Sivaraj B., et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-κB signaling pathway. Sci Signal 2012, 5:ra75.
29. Conte D., Holcik M., Lefebvre C.A., Lacasse E., Picketts D.J., Wright K.E., et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 2006, 26:699-708.
30. Kayagaki N., Warming S., Lamkanfi M., Vande Walle L., Louie S., Dong J., et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011, 479:117-121.
31. Kenneth N.S., Younger J.M., Hughes E.D., Marcotte D., Barker P.A., Saunders T.L., et al. An inactivating caspase 11 passenger mutation originating from the 129 murine strain in mice targeted for c-IAP1. Biochem J 2012, 443:355-359.
32. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
33. Gardam S., Turner V.M., Anderton H., Limaye S., Basten A., Koentgen F., et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 2011, 117:4041-4051.
34. Moulin M., Anderton H., Voss A.K., Thomas T., Wong W.W., Bankovacki A., et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 2012, 31:1679-1691.
35. Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
36. Messina M., Del Giudice I., Khiabanian H., Rossi D., Chiaretti S., Rasi S., et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014, 123:2378-2388.
37. Cortese D., Sutton L.A., Cahill N., Smedby K.E., Geisler C., Gunnarsson R., et al. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 2014, 28:710-713.
38. Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 2011, 118:4930-4934.
39. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
40. Santoro M.M., Samuel T., Mitchell T., Reed J.C., Stainier D.Y. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet 2007, 39:1397-1402.
41. Yeh W.C., Delapompa J.L., Mccurrach M.E., Shu H.B., Elia A.J., Shahinian A., et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998, 279:1954-1958.
42. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998, 9:267-276.
43. Yeh W.C., Itie A., Elia A.J., Ng M., Shu H.B., Wakeham A., et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642.
44. Mahoney D.J., Cheung H.H., Mrad R.L., Plenchette S., Simard C., Enwere E., et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A 2008, 105:11778-11783.
45. Varfolomeev E., Goncharov T., Fedorova A.V., Dynek J.N., Zobel K., Deshayes K., et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008, 283:24295-24299.
46. Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M., Rieser E., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009, 36:831-844.
47. Dillon C.P., Weinlich R., Rodriguez D.A., Cripps J.G., Quarato G., Gurung P., et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014, 157:1189-1202.
48. Kaiser W.J., Daley-Bauer L.P., Thapa R.J., Mandal P., Berger S.B., Huang C., et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci U S A 2014, 111:7753-7758.
49. Rickard J.A., O'Donnell J.A., Evans J.M., Lalaoui N., Poh A.R., Rogers T., et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014, 157:1175-1188.
50. Zhang H., Zhou X., McQuade T., Li J., Chan F.K., Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011, 471:373-376.
51. Kaiser W.J., Upton J.W., Long A.B., Livingston-Rosanoff D., Daley-Bauer L.P., Hakem R., et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011, 471:368-372.
52. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
53. Silke J., Vucic D. IAP family of cell death and signaling regulators. Methods Enzymol 2014, 35-65.
54. Peltzer N., Rieser E., Taraborrelli L., Draber P., Darding M., Pernaute B., et al. HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Rep 2014, 9:153-165.
55. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 2004, 21:629-642.
56. Gardam S., Sierro F., Basten A., Mackay F., Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28:391-401.
57. Chan T.D., Gardam S., Gatto D., Turner V.M., Silke J., Brink R. In vivo control of B-cell survival and antigen-specific B-cell responses. Immunol Rev 2010, 237:90-103.
58. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
59. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
60. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
61. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008, 9:1364-1370.
62. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008, 9:1371-1378.
63. Feltham R., Moulin M., Vince J.E., Mace P.D., Wong W.W., Anderton H., et al. Tumor necrosis factor (TNF) signaling, but Not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem 2010, 285:17525-17536.
64. Varfolomeev E., Goncharov T., Maecker H., Zobel K., Kömüves L.G., Deshayes K., et al. Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci Signal 2012, 5:ra22.
65. Vince J.E., Pantaki D., Feltham R., Mace P.D., Cordier S.M., Schmukle A.C., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-{kappa}B and to prevent TNF-induced apoptosis. J Biol Chem 2009, 284:35906-35915.
66. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004, 279:26243-26250.
67. He J.Q., Saha S.K., Kang J.R., Zarnegar B., Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-κB pathway. J Biol Chem 2007, 282:3688-3694.
68. Sanjo H., Zajonc D.M., Braden R., Norris P.S., Ware C.F. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem 2010, 285:17148-17155.
69. Vince J.E., Chau D., Callus B., Wong W.W., Hawkins C.J., Schneider P., et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008, 182:171-184.
70. Sun S.C. The noncanonical NF-κB pathway. Immunol Rev 2012, 246:125-140.
71. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005, 280:40599-40608.
72. Wong W.W., Vince J.E., Lalaoui N., Lawlor K.E., Chau D., Bankovacki A., et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood 2014, 123:2562-2572.
73. Vince J.E., Wong W.W., Gentle I., Lawlor K.E., Allam R., O'Reilly L., et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012, 36:215-227.
74. Yabal M., Müller N., Adler H., Knies N., Groß C.J., Damgaard R.B., et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep 2014, 7:1796-1808.
75. Condon S.M., Mitsuuchi Y., Deng Y., Laporte M.G., Rippin S.R., Haimowitz T., et al. Birinapant - a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 2014, 57:3666-3677.
76. Labbé K., McIntire C.R., Doiron K., Leblanc P.M., Saleh M. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 2011, 35:897-907.
77. Tan B.M., Zammit N.W., Yam A.O., Slattery R., Walters S.N., Malle E., et al. Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor κB and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells. Diabetologia 2013, 56:520-532.
78. Verhagen A.M., Kratina T.K., Hawkins C.J., Silke J., Ekert P.G., Vaux D.L. Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. Cell Death Differ 2007, 14:348-357.
79. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
80. Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer - from molecular mechanism to therapeutic application. Clin Cancer Res 2014, 20:289-295.
81. Dueber E.C., Schoeffler A.J., Lingel A., Elliott J.M., Fedorova A.V., Giannetti A.M., et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 2011, 334:376-380.
82. Varfolomeev E., Moradi E., Dynek J.N., Zha J., Fedorova A.V., Deshayes K., et al. Characterization of ML-IAP protein stability and physiological role in vivo. Biochem J 2012, 447:427-436.
83. Roy N., Mahadevan M.S., Mclean M., Shutler G., Yaraghi Z., Farahani R., et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178.
84. Qu Y.J., Ge X.S., Bai J.L., Wang L.W., Cao Y.Y., Lu Y.Y., et al. Association of copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein gene with the natural history in a Chinese spinal muscular atrophy cohort. J Child Neurol 2014, (ePub ahead of print), pii: 0883073814553271.
85. Holcik M., Thompson C.S., Yaraghi Z., Lefebvre C.A., MacKenzie A.E., Korneluk R.G. The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc Natl Acad Sci U S A 2000, 97:2286-2290.
86. Yaraghi Z., Diez E., Gros P., MacKenzie A. cDNA cloning and the 5'genomic organization of Naip2, a candidate gene for murine Legionella resistance. Mamm Genome 1999, 10:761-763.
87. Huang S., Scharf J.M., Growney J.D., Endrizzi M.G., Dietrich W.F. The mouse Naip gene cluster on chromosome 13 encodes several distinct functional transcripts. Mamm Genome 1999, 10:1032-1035.
88. Wright E.K., Goodart S.A., Growney J.D., Hadinoto V., Endrizzi M.G., Long E.M., et al. Naip5 affects host susceptibility to the intracellular pathogen Legionella pneumophila. Curr Biol 2003, 13:27-36.
89. Diez E., Lee S.H., Gauthier S., Yaraghi Z., Tremblay M., Vidal S., et al. Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila. Nat Genet 2003, 33:55-60.
90. Zhao Y., Yang J., Shi J., Gong Y.N., Lu Q., Xu H., et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011, 477:596-600.
91. Yang J., Zhao Y., Shi J., Shao F. Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A 2013, 110:14408-14413.
92. Lightfield K.L., Persson J., Brubaker S.W., Witte C.E., von Moltke J., Dunipace E.A., et al. Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol 2008, 9:1171-1178.
93. Boniotto M., Tailleux L., Lomma M., Gicquel B., Buchrieser C., Garcia S., et al. Population variation in NAIP functional copy number confers increased cell death upon Legionella pneumophila infection. Hum Immunol 2012, 73:196-200.
94. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
95. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000, 10:1319-1328.
96. Yue Z., Carvalho A., Xu Z., Yuan X., Cardinale S., Ribeiro S., et al. Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line. J Cell Biol 2008, 183:279-296.
97. Uren A.G., Beilharz T., O'Connell M.J., Bugg S.J., van Driel R., Vaux D.L., et al. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci U S A 1999, 96:10170-10175.
98. Fraser A.G., James C., Evan G.I., Hengartner M.O. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999, 9:292-301.
99. Speliotes E.K., Uren A., Vaux D., Horvitz H.R. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 2000, 6:211-213.
100. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127-134.
101. Qiu X.B., Markant S.L., Yuan J., Goldberg A.L. Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J 2004, 23:800-810.
102. Hao Y., Sekine K., Kawabata A., Nakamura H., Ishioka T., Ohata H., et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 2004, 6:849-860.
103. Hitz C., Vogt-Weisenhorn D., Ruiz P., Wurst W., Floss T. Progressive loss of the spongiotrophoblast layer of Birc6/Bruce mutants results in embryonic lethality. Genesis 2005, 42:91-103.
104. Pohl C., Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell 2008, 132:832-845.
105. Vaux D.L., Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005, 6:287-297.
106. Chai J., Yan N., Huh J.R., Wu J.W., Li W., Hay B.A., et al. Molecular mechanism of Reaper-Grim-Hid-mediated suppression of DIAP1-dependent Dronc ubiquitination. Nat Struct Biol 2003, 10:892-898.
107. Andree M., Seeger J.M., Schüll S., Coutelle O., Wagner-Stippich D., Wiegmann K., et al. BID-dependent release of mitochondrial SMAC dampens XIAP-mediated immunity against Shigella. EMBO J 2014, 33:2171-2187.
108. Hsieh W.C., Chuang Y.T., Chiang I.H., Hsu S.C., Miaw S.C., Lai M.Z. Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice. Blood 2014, 124:2847-2857.
109. Cusack C.L., Swahari V., Hampton Henley W., Michael Ramsey J., Deshmukh M. Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning. Nat Commun 2013, 4:1876.
110. Unsain N., Higgins J.M., Parker K.N., Johnstone A.D., Barker P.A. XIAP regulates caspase activity in degenerating axons. Cell Rep 2013, 4:751-763.
111. Worthey E.A., Mayer A.N., Syverson G.D., Helbling D., Bonacci B.B., Decker B., et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011, 13:255-262.
112. Okada H., Bakal C., Shahinian A., Elia A., Wakeham A., Suh W.K., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004, 199:399-410.
113. Jiang Y., de Bruin A., Caldas H., Fangusaro J., Hayes J., Conway E.M., et al. Essential role for survivin in early brain development. J Neurosci 2005, 25:6962-6970.
114. Jones G., Jones D., Zhou L., Steller H., Chu Y. Deterin, a new inhibitor of apoptosis from Drosophila melanogaster. J Biol Chem 2000, 275:22157-22165.
115. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., Luo W., Devriese A., Lupu F., et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002, 123:619-631.
116. Lotz K., Pyrowolakis G., Jentsch S. BRUCE, a giant E2/E3 ubiquitin ligase and inhibitor of apoptosis protein of the trans-golgi network, is required for normal placenta development and mouse survival. Mol Cell Biol 2004, 24:9339-9350.
117. Wong W.W., Gentle I.E., Nachbur U., Anderton H., Vaux D.L., Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 2010, 17:482-487.